#Medical #health #industry #weekly #report #Yimiao #Shenzhou #completes #million #yuan #financing #biosimilar #drugs #carry #mass #procurement #due #coursedetailed #interpretationnewshot #events36氪
In recent years, innovations in the medical and health industry have continued to emerge and have developed into one of the most active industries. 36 krypton has witnessed and accompanied the growth of innovative companies in this field, and brought professional voices to the industry.
To this end, 36Kr launched the “Medical and Health Industry Weekly Report”, which will be published regularly to provide readers with industry information from multiple perspectives such as capital, policy, finance, and new products.
Please check the weekly report of the medical and health industry on October 18. The industry weekly report contains the financing news reported by the “36Kr Venture Capital Channel” in the medical and health sector this week, as well as other domestic and foreign industry news that deserve attention.
Beijing Nordson Chuanglian Technology Co., Ltd. (hereinafter referred to as: Nordson Chuanglian) has completed a new round of 200 million yuan financing. This round of financing is led by Sequoia China. The old shareholders Jingwei China, Zhichun Capital, Morningside Capital, Volcanic Rock Capital, Creation Partners Capital and Fengrui Capital continued to invest. This is the new round of financing after “Nuoxin Chuanglian” received tens of millions of US dollars in B+ round of financing in June this year, and it is also the third round of financing this year “Nuoxin Chuanglian”. The funds raised in this round of financing will be used for business development, technology investment and solution optimization.
To build a digital bridge between pharmaceutical companies and doctors, “Nuoxin Chuanglian” received a new round of 200 million yuan financing led by Sequoia
It is reported that “Qianglian Zhichuang” has recently completed tens of millions of yuan in Series B financing. This round of financing was led by Shanlan Capital, followed by Qilun Ventures and Qingzhe Ventures, and Probe Capital served as the financial advisor. It is the new first round of financing after the A round of financing invested by Lenovo Star and Tuojin Capital in 2019. Round of financing. This round of funds will be mainly used to promote the commercialization and implementation of the company’s stroke diagnosis and treatment products.
Focus on precise diagnosis and treatment of cerebrovascular diseases, “Qianglian Zhichuang” completed tens of millions of yuan in Series B financing
Yikesai Biotechnology (Taicang) Co., Ltd. (Yikesai Bio) completed a new round of nearly 100 million yuan in financing. This round of financing was led by Yonghua Investment, followed by Zhongguancun Development Frontier Enterprise Investment Fund, Suzhou Yajie Angel Investment, and Yao Kun Technology. The financing funds are mainly used to build a serum-free culture medium GMP production workshop, further expand overseas serum factories, increase production capacity, and accelerate the construction of overseas marketing networks.
Mapuqi Medical (Shenzhen Mapuqi Medical Technology Co., Ltd.) received tens of millions of B rounds of financing. This round of financing was invested by Sanze Ventures and Ruifeng Kangqi. Mr. Fu Xuesen, chairman of Mapuche Medical, said that the funds will be used for the expansion of the Japanese R&D center and the promotion of domestic and foreign markets.
It is reported that the biotechnology company “Boya Jiyin” today announced the completion of a 450 million yuan B round of financing. This round of financing was led by Sanzheng Health Investment, followed by Sequoia Capital China Fund, Yahui Investment, and Kunlun Capital. The company’s existing investors IDG Capital, Eli Lilly Asia Fund, Huagai Capital, and Songhe Capital participated in the investment.
Gene editing therapy was favored by capital again, “Bo Ya Ji Yin” completed 450 million yuan in round B financing
It is reported that “Elp” has recently completed 50 million A+ round of financing. This round of financing was led by Nanjing Dynamic Balance Capital and old shareholder Lenovo Star, and all old shareholders such as Ziniu Fund and Nanjing Hi-Tech followed the investment. The funds raised in this round of financing will be mainly used for IND applications from China and the United States, and will continue to increase the advantages of industrialized production lines, improve and optimize downstream somatic cell production and preparation processes, and push regenerative medicine cell products into clinical trials. At the same time, it will also be used to develop innovative drug delivery routes, expand different dosage forms and product forms of regenerative heart cell products, and broaden the application scenarios of heart failure treatment.
Focusing on iPSC induced pluripotent stem cell technology, “Elpu” completed 50 million A+ round financing
It is reported that “Core Medical” has recently completed a round of financing of nearly 100 million yuan. This round of financing was led by Lianxin Capital, followed by PricewaterhouseCoopers and Yifeng Capital. It is a new round of financing following the tens of millions of yuan in angel financing completed by “Core Medical” in November 2019. The funds raised in this round of financing will be mainly used for clinical research of miniaturized magnetic levitation artificial heart and new product development.
Focusing on the research and development of miniaturized magnetic levitation artificial heart, “Core Medical” completed nearly 100 million yuan of A round of financing
It is reported that “Zhidao Bio” has recently completed a series B financing of more than 100 million yuan. This round of financing was jointly invested by Yijing Capital, Qiaojing Capital and Chang Development. Prior to this, “Zhidao Bio” has successively received investment from Sherpa Investment, Powerfang Capital, Qirong Venture Capital, Waige Capital and other institutions. The funds raised in this round of financing will be mainly used for preclinical pharmacology, pharmacological and toxicological studies of anti-tumor long-acting cytokine drugs, and clinical phase I and II international multi-center studies.
Focusing on the research and development of cytokine drugs, “Zhidao Bio” has completed more than 100 million yuan of round B financing
Yimiao Shenzhou announced that it has completed a 100 million yuan C+ round of financing. The funds raised this time will be mainly used to support the company’s new tumor product pipeline research and development and accelerate the product launch process. Yimiao Shenzhou is a cutting-edge biomedical company dedicated to applying innovative gene cell medicine technology to the treatment of malignant tumors.
The biotechnology company Glycostem Therapeutics announced that its research product oNKord® has been designated as an “orphan drug” by the FDA for the treatment of patients with multiple myeloma (MM). The designation will provide Glycostem with certain incentives, such as obtaining seven-year market exclusivity and FDA’s specific and clear guidance on the development of rare diseases.
The UroCAD product kit developed by Hongyuan Biotechnology can accurately detect urinary system cancers. When used to detect urothelial cancer, the specificity and sensitivity are up to 82% and 96%, respectively, and the sensitivity for high-grade cancer is 93%. Hongyuan Bio is currently the only company on the market that can use chromosome detection methods for urinary cancer at home. The company uses second-generation sequencing technology and artificial intelligence algorithms to make the detection process fully automatic without the assistance of a doctor. Patients can take samples anytime and anywhere, and the detection is automatically completed.
From the “ward” to the “home” era, “Hongyuan Bio” launched a highly accurate urinary cancer screening product
Varian has been granted an Research Equipment Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the first clinical trial of FLASH therapy, which is an experimental treatment model for radiotherapy at ultra-high dose rates. FLASH therapy involves an ultra-high dose rate, which is usually completed in less than a second, and its speed may be more than 100 times faster than traditional radiotherapy. This research, named FAST-01, will involve the research use of Varian’s ProBeam particle accelerator. After improvement, it will provide advanced non-invasive treatment options for cancer patients.
Biopharmaceutical company immunomedics announced that the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan drug designation for the treatment of adult and child glioblastoma patients. The designation of “orphan drugs” makes the company eligible for various development incentives, including tax relief for qualified clinical research, exemption from new drug application fees, and a designated market exclusivity period after approval.
Biopharmaceutical company Inventiva announced that the US FDA has granted the company’s main drug candidate lanifibranor breakthrough therapy designation for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is an oral small-molecule pan-PPAR agonist, which produces a balanced activation of PPARα and PPARδ, and can partially activate PPARγ, inducing anti-fibrosis, anti-inflammatory responses, and beneficial vascular and metabolic changes in the body.
Genomic medicine company Lucence announced the release of the world’s first DeepMARK™ subgenomic RNA (sgRNA) kit for direct detection of novel coronavirus (SARS-CoV-2). The DeepMARK™ next-generation sequencing kit uses amplicon-based next-generation sequencing (NGS) technology to simultaneously analyze the new coronavirus genome and subgenomic RNA in a single sequence, helping scientists quickly trace the source of infection and determine the infectivity of the virus. And guide vaccine research and development.
To help track the source of the new coronavirus infection, “Lusheng Bio” released the world’s first new coronavirus subgenomic RNA detection kit
Biotec’s application for the listing of a new class 1 drug batifiban injection was accepted by CDE for perioperative antithrombotic use in PCI. There are many types of anti-platelet agglutination drugs. Among them, IIb/IIIa receptor antagonists have the characteristics of strong drug effect and stable effect, and are widely used in venous and coronary anticoagulation. Battifiban is a synthetic platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist.
Li’s major pharmaceutical company announced that Zhaoke (Guangzhou) Ophthalmic Medicine Co., Ltd. (hereinafter referred to as “Zhaoke Ophthalmology”), its ophthalmic drug company, has signed contracts with investment institutions including TPG, and raised a total of US$145 million. The subscription was jointly led by Hillhouse Capital and TPG Asia. A total of 11 investors participated in this financing, and the specific investment amount of each investment institution has not been announced. After the subscription is completed, Detai Investment and Hillhouse Capital will each hold 7.441% of Zhaoke Ophthalmology.
Policies and regulations
In its response to Recommendation No. 5348 of the Third Session of the Thirteenth National People’s Congress, the National Medical Security Administration mentioned: The National Medical Insurance Administration is studying policies related to the centralized procurement of biological products. Biological analogues are not restricted areas for centralized procurement. Based on factors such as the similarity of the company’s production capacity and the stability of the supply chain, and the clinical substitutability of specific products, centralized procurement will be carried out in a timely manner.
The official website of the National Health Commission issued the “Opinions on Strengthening the Construction of the National Health Information Standardization System”, which pointed out that the exploration of the standardized construction of medical and health blockchain technology applications. Explore and study the application scenarios of blockchain in the medical and health field, accelerate the research and formulation of blockchain information service standards in the medical and health field, and strengthen the standard and guide the integrated application of blockchain technology and the medical and health industry. Strengthen data interconnection and data traceability, and encourage medical and health institutions to explore the use of blockchain technology in medical consortia, personal health records, electronic prescriptions, drug management, medical insurance, smart hospital management, vaccine management, and genetics while ensuring safety. Applications such as sequencing.
The Comprehensive Department of the State Drug Administration has publicly solicited opinions on the “Administrative Measures for Vaccine Liability Compulsory Insurance (Draft for Solicitation of Comments)”. The draft opinion clarifies the scope of insurance liability, and stipulates that the insurance liability of compulsory vaccine liability insurance shall be the financial compensation liability that the vaccine marketing license holder shall bear in accordance with the law if the vaccine quality problem causes the injury or death of the recipient. At the same time, it stipulates the limit of liability for claims: the mandatory insurance for immunization program vaccines and non-immunization program vaccines has a uniform minimum liability limit nationwide. The death compensation shall be no less than 500,000 yuan per person, and the disability compensation shall be determined according to the disability degree appraisal issued by the disability appraisal agency.
The State Food and Drug Administration issued an announcement on the construction of an information traceability system for key varieties. The announcement requires the implementation of the “Drug Administration Law” and the State Council’s deployment on drug traceability, actively promote the construction of drug information traceability system, improve the level and efficiency of drug supervision, and effectively ensure drug quality and safety. The holder of the drug marketing license shall implement the main responsibility for the entire process of drug quality management, establish an informatized traceability system, collect traceability information of the entire process, and basically realize the selected varieties, narcotic drugs, and narcotic drugs in the national centralized drug procurement by December 31, 2020. Key varieties such as psychotropic drugs and blood products can be traced.
Jinling Pharmaceutical released its first three quarters performance forecast. In the first three quarters, the net profit attributable to shareholders of listed companies was 70.91 million yuan to 99.28 million yuan, a year-on-year decrease of 58%-70%. Regarding the performance changes, Jinling Pharmaceutical said that the main reason is that the company expects that the impact of non-recurring gains and losses on the net profit attributable to shareholders of the listed company during the reporting period is about -30 million yuan. Jiangsu Zijin Rural Commercial Bank Co., Ltd. Due to changes in income from changes in the fair value of stocks.
Yuexin Health released its first three quarters performance forecast. In the first three quarters, the net profit attributable to shareholders of listed companies was 52 million yuan to 55 million yuan, a year-on-year increase of 51.97%-60.73%. Yuexin Health stated that during the first three quarters, although the company was affected by the new crown pneumonia epidemic, its operating income only slightly decreased, but its operating profit increased. In the first half of the year, the company changed the credit loss rate of receivables from the building materials business. After the change in accounting estimates, the amount of bad debt losses accrued decreased, increasing the net profit attributable to shareholders of the listed company by approximately 17 million yuan.
Winner Medical disclosed its first three quarters performance forecast. The company expects the net profit attributable to owners of the parent company from January to September 2020 to be between RMB 3,037 million and RMB 3,237 million, a year-on-year increase of 651% to 700%. Affected by the epidemic, the company’s sales of medical protective equipment (mainly masks, protective clothing, surgical gowns, and isolation gowns) have increased significantly; the company’s self-developed cotton spunlace non-woven materials are widely used in surgical gowns, isolation gowns, and protective clothing And other products, its comfort, breathability and other advantages have been highly recognized by domestic and foreign customers. The company has rapidly expanded its production capacity to meet market demand; because independent research and development of raw materials are widely used in protective products, it has achieved large-scale production, thus enabling The increase in product cost advantage has brought about a substantial increase in third-quarter performance.
Editor: Dun Yuting
36氪Pro is the WeChat public account of 36氪